138 related articles for article (PubMed ID: 21488964)
1. Aglepristone decreases proliferation in progesterone receptor-positive canine mammary carcinomas.
Guil-Luna S; Sánchez-Céspedes R; Millán Y; De Andrés FJ; Rollón E; Domingo V; Guscetti F; Martín de Las Mulas J
J Vet Intern Med; 2011; 25(3):518-23. PubMed ID: 21488964
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of neoadjuvant aglepristone treatment in clinicopathological parameters of progesterone receptor-positive canine mammary carcinomas.
Guil-Luna S; Millán Y; De Andres J; Rollón E; Domingo V; García-Macías J; Sánchez-Céspedes R; Martín de Las Mulas J
Vet Comp Oncol; 2017 Jun; 15(2):391-399. PubMed ID: 26781329
[TBL] [Abstract][Full Text] [Related]
3. Progesterone receptor isoform A may regulate the effects of neoadjuvant aglepristone in canine mammary carcinoma.
Guil-Luna S; Stenvang J; Brünner N; De Andrés FJ; Rollón E; Domingo V; Sánchez-Céspedes R; Millán Y; Martín de Las Mulas J
BMC Vet Res; 2014 Dec; 10():296. PubMed ID: 25515784
[TBL] [Abstract][Full Text] [Related]
4. Comparison of steroid receptor expression in normal, dysplastic, and neoplastic canine and feline mammary tissues.
Millanta F; Calandrella M; Bari G; Niccolini M; Vannozzi I; Poli A
Res Vet Sci; 2005 Dec; 79(3):225-32. PubMed ID: 16054892
[TBL] [Abstract][Full Text] [Related]
5. Aglepristone (RU534) effects on luteal function of pseudopregnant rabbits: steroid receptors, enzymatic activities, and hormone productions in corpus luteum and uterus.
Parillo F; Dall'Aglio C; Brecchia G; Maranesi M; Polisca A; Boiti C; Zerani M
Anim Reprod Sci; 2013 Apr; 138(1-2):118-32. PubMed ID: 23517855
[TBL] [Abstract][Full Text] [Related]
6. Progesterone receptor isoform analysis by quantitative real-time polymerase chain reaction in formalin-fixed, paraffin-embedded canine mammary dysplasias and tumors.
Guil-Luna S; Stenvang J; Brünner N; Sánchez-Céspedes R; Millán Y; Gómez-Laguna J; de las Mulas JM
Vet Pathol; 2014 Sep; 51(5):895-902. PubMed ID: 24249219
[TBL] [Abstract][Full Text] [Related]
7. Oestrogen and progesterone receptor expression in subtypes of canine mammary tumours in intact and ovariectomised dogs.
Mainenti M; Rasotto R; Carnier P; Zappulli V
Vet J; 2014 Oct; 202(1):62-8. PubMed ID: 24980810
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of melatonin treatment in primary culture of canine mammary tumors.
Lopes JR; Maschio LB; Jardim-Perassi BV; Moschetta MG; Ferreira LC; Martins GR; Gelaleti GB; De Campos Zuccari DA
Oncol Rep; 2015 Jan; 33(1):311-9. PubMed ID: 25384569
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of the use of aglepristone, with or without cloprostenol, to treat cystic endometrial hyperplasia-pyometra complex in bitches.
Fieni F
Theriogenology; 2006 Oct; 66(6-7):1550-6. PubMed ID: 16563489
[TBL] [Abstract][Full Text] [Related]
10. Hormonal variation in bitches after early or mid-pregnancy termination with aglepristone (RU534).
Fieni F; Martal J; Marnet PG; Siliart B; Bernard F; Riou M; Bruyas JF; Tainturier D
J Reprod Fertil Suppl; 2001; 57():243-8. PubMed ID: 11787157
[TBL] [Abstract][Full Text] [Related]
11. A retrospective study of bitches with pyometra, medically treated with aglepristone.
Ros L; Holst BS; Hagman R
Theriogenology; 2014 Dec; 82(9):1281-6. PubMed ID: 25234791
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of clinicopathological characteristics and oestrogen receptor gene expression in oestrogen receptor-negative, progesterone receptor-positive canine mammary carcinomas.
Kim NH; Lim HY; Im KS; Shin JI; Kim HW; Sur JH
J Comp Pathol; 2014 Jul; 151(1):42-50. PubMed ID: 24913515
[TBL] [Abstract][Full Text] [Related]
13. Treatment of growth hormone excess in dogs with the progesterone receptor antagonist aglépristone.
Bhatti SF; Duchateau L; Okkens AC; Van Ham LM; Mol JA; Kooistra HS
Theriogenology; 2006 Sep; 66(4):797-803. PubMed ID: 16497368
[TBL] [Abstract][Full Text] [Related]
14. Molecular studies on oestrogen α and progesterone receptors and histomorphometric analysis of canine uteri following aglepristone treatment.
Limmanont C; Lertwatcharasarakul P; Ponglowhapan S; Sirinarumitr K
Reprod Domest Anim; 2021 Jul; 56(7):1015-1023. PubMed ID: 33914997
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of hormone receptor expression for use in predicting survival of female dogs with malignant mammary gland tumors.
Chang CC; Tsai MH; Liao JW; Chan JP; Wong ML; Chang SC
J Am Vet Med Assoc; 2009 Aug; 235(4):391-6. PubMed ID: 19681719
[TBL] [Abstract][Full Text] [Related]
16. A prospective analysis of immunohistochemically determined estrogen receptor alpha and progesterone receptor expression and host and tumor factors as predictors of disease-free period in mammary tumors of the dog.
de Las Mulas JM; Millán Y; Dios R
Vet Pathol; 2005 Mar; 42(2):200-12. PubMed ID: 15753474
[TBL] [Abstract][Full Text] [Related]
17. Receptors for oestrogen, progesterone and epidermal growth factor in normal and tumorous canine mammary tissues.
Donnay I; Rauïs J; Wouters-Ballman P; Devleeschouwer N; Leclercq G; Verstegen JP
J Reprod Fertil Suppl; 1993; 47():501-12. PubMed ID: 8229969
[TBL] [Abstract][Full Text] [Related]
18. Effects of aglepristone, a progesterone receptor antagonist, in a dog with a vaginal fibroma.
Rollón E; Millán Y; de las Mulas JM
J Small Anim Pract; 2008 Jan; 49(1):41-3. PubMed ID: 17784929
[TBL] [Abstract][Full Text] [Related]
19. Estrogen and progesterone receptor status of mammary carcinomas and correlation with clinical outcome in dogs.
Sartin EA; Barnes S; Kwapien RP; Wolfe LG
Am J Vet Res; 1992 Nov; 53(11):2196-200. PubMed ID: 1466519
[TBL] [Abstract][Full Text] [Related]
20. COX-2 expression in canine and feline invasive mammary carcinomas: correlation with clinicopathological features and prognostic molecular markers.
Millanta F; Citi S; Della Santa D; Porciani M; Poli A
Breast Cancer Res Treat; 2006 Jul; 98(1):115-20. PubMed ID: 16538539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
